Investigational Drug for Adults with Advanced Solid Tumors

Inclusion Criteria

• Have a diagnosis of advanced solid tumor with documented MAPK-pathway alteration (KRAS, BRAF Class II/Class III, or NF1 LOF) or diagnosis of Chordoma Cancer.
• Have measureable disease confirmed by Computerized Tomograpy scan (CT) or Magnetic Resonance Imaging (MRI).
• Be capable of independently managing all self-care and be ambulatory and up and about at least 50% of each day (normal waking hours).
• Be able to swallow oral medication (capsules) without chewing, crushing, or opening.
• Be willing to record daily intake of study drug on a paper diary.

Exclusion Criteria

• Have history of significant cardiovascular disease.
• Have received radiotherapy or proton therapy within 1 Week of the start of study treatment.
• Have undergone major surgery within 4 Weeks of starting study treatment.
• Have a diagnosis of another invasive malignancy within the previous 3 Yrs (curatively treated malignancies not expected to require additional treatment are excluded).
• Have a gastrointestinal illness (ie_Crohn's Disease, Celiac Disease, or chronic gastritis) that may interfere with absorption of the oral study drug.
• Be on dialysis.
• Be pregnant or trying to get pregnant.

Additional Info

• All study-related visits during the course of this clinical trial will occur at Scripps Clinic Torrey Pines (Geisel Pavilion).
• Search NCT04528836 at https://clinicaltrials.gov website for more information.